Strategic partnerships Capitalize on BiVACOR’s collaborations with reputable institutions like Texas Heart Institute and Seattle scientific leadership to position co-development and joint clinical trial opportunities with hospitals, systems, and academic centers that treat advanced heart failure.

Regulatory milestone Leverage the FDA Breakthrough Designation to accelerate discussions with procurement teams and payers about early access programs, reimbursement pathways, and potential pilot deployments in transplant-needy patient populations.

Clinical adoption Target high-volume transplant and cardiothoracic centers for initial implants and feasibility programs, highlighting the device’s MAGLEV, single moving part design, and biocompatibility advantages to drive clinical trial enrollment and surgeon adoption.

Funding momentum Align sales outreach with BiVACOR’s recent funding and investor activity to underscore financial backing and long-term viability when engaging hospital administrators and finance teams for capital procurement.

Market positioning Differentiate BiVACOR from competitors by emphasizing its compact size, durable non-contact rotor technology, and potential to serve a broader patient body surface area, opening conversations about expanding patient eligibility and reimbursement uptake.